2Hochberg MD,Altman RD,Brandt KD,et al.guidelines for the medical management of osteoarthritis:part Ⅱ ,osteoarthritis of the knee[J].Arthritis Rheum, 1995,38:1541-1546.
3Ahmad SR,Kortepeter C,Brinker A,et al. Renal failure associated with the use of celecoxib and rofecoxib [J]. Drug Safety,2002,25:537-544.
4Reginster JY,Deroisy R,Rovati LC,et al. Longterm effects of glucosmine sulphate on osteoarthritis progression: a randomised,placebo controlled clinical trial [J]. Lancet,2001,357:251-256.
5Pavelka K,Catterovd J,Clejarovd M,et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis [J]. Arch Intern Med,2002,162:2113-2123.
6Mendes AF,Caramona MM,Carvalho AP,et al.Diacerhein and rhein prevent interleukin-1 beta induced nuclear factor kappa B activation by inhibiting the degradation of inhibitor kappa B Alpha [J]. Pharmacol Toxicol,2002,91:22-28.
7Simonian PT,Sussmann PS,Wickiewicz,et al.Contact pressures at osteochondral donor sites in the knee [J].Am J Sports Med,1998,26:491-494.
8Gabriel SE,Crowson CS,O`Fallon WM. Costs of osteoarthritis:estimates from a geographically defined population[J]. J Pheumatol, 1995,22(suppl 43) :23-25.
9Adams ME,Ackinson MH,Lussier AJ,et al.The role of viscosupplementation with hylan G-F 20 in the treatment of osteoarthtitis of the knee:a canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti -inflammatory drugs (NSAIDS) and NSAIDS alone [J]. Osteoarth Cartil, 1995,3:213-225.
10Steinmeyer J,Daufeldt S,Kalbhen DA. The proteoglycan metabolism,morphol- ogy and viability of articular cartilage treated with a synthetic matrix metalloproteinase inhibitor.Res Exp Med(berl) [J]. 1997,197(2):63.
